Drug-induced liver injury (DILI) can broadly be divided into predictable and dose dependent
such as acetaminophen (APAP) and unpredictable or idiosyncratic DILI (IDILI). Liver injury …

Idiosyncratic drug-induced liver injury (DILI) is a type of hepatic injury caused by an
uncommon drug adverse reaction that can develop to conditions spanning from …

Preclinical toxicity studies have demonstrated that exposure of laboratory animals to liver
enzyme inducers during preclinical safety assessment results in a signature of toxicological …

This review brings you up-to-date with the hepatocyte research on: 1) in vitro–in vivo
correlations of metabolism and clearance; 2) CYP enzyme induction, regulation, and cross …

Drug-induced liver injury (DILI) is the most common adverse event causing drug
nonapprovals and drug withdrawals. Using drugs as test agents and measuring a panel of …

Thiophene is a five-membered, sulfur-containing heteroaromatic ring commonly used as a
building block in drugs. It is considered to be a structural alert, as its metabolism can lead to …

The nonsteroidal antiinflammatory drug diclofenac causes rare but significant cases of
serious hepatotoxicity, typically with a delayed onset (> 1–3 months). Because there is no …

Rare adverse reactions to drugs that are of unknown etiology, or idiosyncratic reactions, can
produce severe medical complications or even death in patients. Current hypotheses …

A number of therapeutic drugs with different structures and mechanisms of action have been
reported to undergo metabolic activation by Phase I or Phase II drug-metabolizing enzymes …

Idiosyncratic drug-induced liver injury (DILI) is a major clinical problem and poses a
considerable challenge for drug development as an increasing number of successfully …